Pharmaceuticals & Biotech|Product Engineering|Increase Efficiency

Tangram TherapeuticsDrug discovery

Target assessments took a full quarter. Now, AI agents synthesize 1,000+ datasets to finish in hours.

Jan 25, 2026|11 days ago

Key results

Assessment Speed
up to 50x
Data Processing Volume
300x

The company

Tangram Therapeutics logo

Tangram Therapeutics

tangramtx.com

Biotech platform for computational drug discovery and RNAi medicines.

IndustryPharmaceuticals & Biotech
LocationLondon, United Kingdom
Employees11-50
Founded2021

Result highlights

  • Up to 50x faster target assessment
  • 300x increase in data processing volume

The story

A UK-based biotech company merging biology and computation to accelerate the discovery of RNA interference (RNAi) medicines for diseases with significant unmet needs.

Traditional drug discovery timelines were prohibitively slow, with document processing taking weeks and target-indication assessments requiring a full quarter. Scientists struggled to synthesize massive amounts of proprietary and public data to identify novel gene targets using legacy deep learning models.

The company developed an agentic AI platform on AWS that orchestrates multiple Large Language Models via Amazon Bedrock to analyze over 1,000 biological datasets. The system uses Retrieval Augmented Generation and document processing pipelines to synthesize internal lab results and public data, while embedding subject matter expertise directly into prompt design. A modular architecture allows the team to continuously benchmark and swap in new models as technology evolves.

Quotes

Explore similar

Find AI opportunities for your
business context

Understand what's working with 2,383 recent AI case studies across industries. We structure things so you can find high-impact strategies for your exact context.

Graphic placeholder

Industries covered